Publications
358 results found
Labella M, Antonio Cespedes J, Dona I, et al., 2022, The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine, ALLERGY, Vol: 77, Pages: 2067-2079, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 18
Boyle RJ, Shamji MH, 2022, Clinical and Experimental Allergy boycotts formula advertising, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 828-829, ISSN: 0954-7894
Shamji MH, Boyle RJ, Roberts G, 2022, Prize-winning abstracts from BSACI/WAO 2022 meeting, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 830-832, ISSN: 0954-7894
Labella M, Cespedes JA, Dona I, et al., 2022, Reply to correspondence: Basophil reactivity to BNT162b2 in COVID-19 convalescence, ALLERGY, Vol: 77, Pages: 2266-2267, ISSN: 0105-4538
Farraia M, Paciencia I, Castro Mendes F, et al., 2022, Allergen immunotherapy for asthma prevention: A systematic review and meta-analysis of randomized and non-randomized controlled studies, ALLERGY, Vol: 77, Pages: 1719-1735, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 12
Agache I, Palmer E, Sanver D, et al., 2022, Molecular allergology approach to allergic asthma, MOLECULAR ASPECTS OF MEDICINE, Vol: 85, ISSN: 0098-2997
- Author Web Link
- Cite
- Citations: 4
Shamji MH, Boyle RJ, 2022, Biomarkers of airway inflammation and immunotherapy, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 726-728, ISSN: 0954-7894
Boyle RJ, Shamji MH, 2022, Early origins of allergic disease, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 592-594, ISSN: 0954-7894
Shamji MH, Boyle RJ, 2022, Immune modulation and the role of innate immune cells in allergy and asthma, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 474-475, ISSN: 0954-7894
Liu Z, Gao P, Shamji MH, 2022, Editorial: The Spectrum of Lymphoid Subsets in Allergic Diseases: Immune Regulation and Immunotherapy, FRONTIERS IN IMMUNOLOGY, Vol: 13, ISSN: 1664-3224
Boyle RJ, Krishna MT, Shamji MH, 2022, Allergy in India-a call for submissions, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 364-366, ISSN: 0954-7894
Shamji MH, Sharif H, Layhadi JA, et al., 2022, Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 149, Pages: 791-801, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 30
Turner P, Darbar R, Shamji M, et al., 2022, Longer Duration Of Peanut Oral Immunotherapy At A Reduced Dosing Frequency Increases The Rate Of Sustained Unresponsiveness Without Reducing Clinical Efficacy, Publisher: MOSBY-ELSEVIER, Pages: AB139-AB139, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 1
Shamji M, Layhadi J, Turner P, et al., 2022, Virus Like Particle (VLP) Based Peanut Allergen Immunotherapy Candidate Display A Decreased Activation And Histamine Release From CRTH2+Basophils: A Proof of Concept Study, Publisher: MOSBY-ELSEVIER, Pages: AB37-AB37, ISSN: 0091-6749
Layhadi J, Palmer E, Drazdauskaite G, et al., 2022, Modulation of T and B cell Responses by Virus-like particle (VLP) Expressing Peanut Allergen Ara h 2: A Novel Vaccine Candidate for Peanut Allergy, Publisher: MOSBY-ELSEVIER, Pages: AB320-AB320, ISSN: 0091-6749
Palmer E, Layhadi J, Fedina O, et al., 2022, IL-10+regulatory B cells are dysregulated in patients with seasonal and perennial allergy, Publisher: MOSBY-ELSEVIER, Pages: AB95-AB95, ISSN: 0091-6749
Layhadi J, Lenormand M, Kirtland M, et al., 2022, Novel machine learning-led discovery of adjuvant drug candidate for allergen immunotherapy using synthetic toll-like receptor 2/6 agonist, Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), Publisher: MOSBY-ELSEVIER, Pages: AB71-AB71, ISSN: 0091-6749
Pfaar O, Bousquet J, Durham SR, et al., 2022, One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence, ALLERGY, Vol: 77, Pages: 454-468, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 22
Shamji MH, Boyle RJ, 2022, Biomarker strategies for perioperative hypersensitivity reactions and severe eosinophilic asthma, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 216-218, ISSN: 0954-7894
Boyle RJ, Shamji MH, 2022, Milk allergy over-diagnosis, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 4-6, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 1
Tan TJ, Delgado-Dolset MI, Escribese MM, et al., 2022, Biomarkers of AIT: Models of prediction of efficacy., Allergol Select, Vol: 6, Pages: 267-275
Allergic rhinitis is an IgE-mediated inflammation that remains a clinical challenge, affecting 40% of the UK population with a wide range of severity from nasal discomfort to life-threatening anaphylaxis. It can be managed by pharmacotherapeutics and in selected patients by allergen immunotherapy (AIT), which provides long-term clinical efficacy, especially during peak allergy season. However, there are no definitive biomarkers for AIT efficacy. Here, we aim to summarize the key adaptive, innate, humoral, and metabolic advances in biomarker identification in response to AIT. Mechanisms of efficacy consist of an immune deviation towards TH1-secreting IFN-γ, as well as an induction of IL10+ cTFR and TREG have been observed. TH2 cells undergo exhaustion after AIT due to chronic allergen exposure and correlates with the exhaustion markers PD-1, CTLA-4, TIGIT, and LAG3. IL10+ DCREG expressing C1Q and STAB are induced. KLRG1+ IL10+ ILC2 were shown to be induced in AIT in correlation with efficacy. BREG cells secreting IL-10, IL-35, and TGF-β are induced. Blocking antibodies IgG, IgA, and IgG4 are increased during AIT; whereas inflammatory metabolites, such as eicosanoids, are reduced. There are multiple promising biomarkers for AIT currently being evaluated. A panomic approach is essential to better understand cellular, molecular mechanisms and their correlation with clinical outcomes. Identification of predictive biomarkers of AIT efficacy will hugely impact current practice allowing physicians to select eligible patients that are likely to respond to treatment as well as improve patients' compliance to complete the course of treatment.
Beirag N, Kumar C, Madan T, et al., 2022, Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation., Front Immunol, Vol: 13
Lung surfactant protein D (SP-D) and Dendritic cell-specific intercellular adhesion molecules-3 grabbing non-integrin (DC-SIGN) are pathogen recognising C-type lectin receptors. SP-D has a crucial immune function in detecting and clearing pulmonary pathogens; DC-SIGN is involved in facilitating dendritic cell interaction with naïve T cells to mount an anti-viral immune response. SP-D and DC-SIGN have been shown to interact with various viruses, including SARS-CoV-2, an enveloped RNA virus that causes COVID-19. A recombinant fragment of human SP-D (rfhSP-D) comprising of α-helical neck region, carbohydrate recognition domain, and eight N-terminal Gly-X-Y repeats has been shown to bind SARS-CoV-2 Spike protein and inhibit SARS-CoV-2 replication by preventing viral entry in Vero cells and HEK293T cells expressing ACE2. DC-SIGN has also been shown to act as a cell surface receptor for SARS-CoV-2 independent of ACE2. Since rfhSP-D is known to interact with SARS-CoV-2 Spike protein and DC-SIGN, this study was aimed at investigating the potential of rfhSP-D in modulating SARS-CoV-2 infection. Coincubation of rfhSP-D with Spike protein improved the Spike Protein: DC-SIGN interaction. Molecular dynamic studies revealed that rfhSP-D stabilised the interaction between DC-SIGN and Spike protein. Cell binding analysis with DC-SIGN expressing HEK 293T and THP- 1 cells and rfhSP-D treated SARS-CoV-2 Spike pseudotypes confirmed the increased binding. Furthermore, infection assays using the pseudotypes revealed their increased uptake by DC-SIGN expressing cells. The immunomodulatory effect of rfhSP-D on the DC-SIGN: Spike protein interaction on DC-SIGN expressing epithelial and macrophage-like cell lines was also assessed by measuring the mRNA expression of cytokines and chemokines. RT-qPCR analysis showed that rfhSP-D treatment downregulated the mRNA expression levels of pro-inflammatory cytokines and chemokines such as TNF-α, IFN-α, IL-1β, IL- 6, IL-8
Shamji MH, Boyle RJ, 2021, Allergic diseases and novel targets in allergen immunotherapy, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 51, Pages: 1526-1528, ISSN: 0954-7894
Shamji MH, Boyle RJ, Fox AT, 2021, Prize-winning abstracts from BSACI 2021 meeting, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 51, Pages: 1529-1530, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 2
Shamji MH, Valenta R, Jardetzky T, et al., 2021, The role of allergen-specific IgE, IgG and IgA in allergic disease, ALLERGY, Vol: 76, Pages: 3627-3641, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 71
Boyle RJ, Shamji MH, 2021, Developments in the field of allergy in 2020 through the eyes of Clinical and Experimental Allergy, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 51, Pages: 1531-1537, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 1
Boyle RJ, Shamji MH, 2021, Making causal inferences in allergy epidemiology studies, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 51, Pages: 1404-1406, ISSN: 0954-7894
Raskopf E, Zeyen C, Singh J, et al., 2021, Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids increases significantly bet v1 specific immunoglobulins in birch pollen allergic patients in a dose-dependent manner, Publisher: WILEY, Pages: 23-23, ISSN: 0105-4538
Testera-Montes A, Eguiluz-Gracia I, Jurado-Escobar R, et al., 2021, Long-term effect of subcutaneous dermatophagoides pteronyssinus-immunotherapy in local allergic rhinitis patients, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 9-9, ISSN: 0105-4538
Layhadi JA, Lenormand MM, Sharif H, et al., 2021, Allergenicity and immunogenicity profile of depigmented-polymerized phleum pratense extract for use in allergen-specific immunotherapy treatments, Publisher: WILEY, Pages: 427-428, ISSN: 0105-4538
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.